Due to a limited supply, we are unable to accept phone calls to schedule COVID-19 vaccinations.
For the most up-to-date information, please check our COVID-19 Vaccination Website.

 

Additional Coronavirus Updates >

MENU

Matthew R. Zibelman, MD

Matthew Zibelman, MD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Assistant Professor, Department of Hematology/Oncology

Research Program

Treatment Philosophy

I am a medical oncologist specializing in the treatment of genitourinary cancers.  As a medical oncologist, I work with patients at all phases of malignant disease, which allows me the opportunity to join patients and families on a journey that can be at times both exhilarating and exhausting.  I understand that the patient-oncologist relationship is a unique partnership and one that I take seriously.  The journey of cancer provides access to moments in life that can be emotionally challenging for all parties, and I view my role as one ultimately about providing information and guidance to help navigate the path in the way best suited to each patient.

I find genitourinary oncology to be a particularly satisfying and exciting field within medical oncology.  It includes a diverse group of patients and a variety of different disease with their own unique opportunities and challenges.  It is an area involved in a great deal of research, which has afforded new treatment options for patients, and allows me to be involved in helping patients live longer, live better, and in some instances, even help cure them of their disease.    

Fortunately, at Fox Chase Cancer Center, our faculty and staff are dedicated and united towards one goal – optimally treating patients with cancer.  I completed my oncology training at Fox Chase and was fortunate to be able to continue as an attending physician at this world-class institution.  As part of Fox Chase, our patients have access to the cutting edge of clinical oncology, including the ability to have access to exciting new drugs as part of clinical trials.  Medical oncology is a rapidly evolving world, with new treatments and possibilities continually being made available to improve patient outcomes, and Fox Chase strives to remain at the forefront of those changes. 

Education and Training

Educational Background

  • Fellow, Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Resident, Internal Medicine, University of Illinois at Chicago Medical Center, Chicago, IL
  • MD, Lewis Katz School of Medicine, Temple University, Philadelphia, PA

Memberships

  • Society for Immunotherapy of Cancer
  • American Society of Clinical Oncology
  • American Society of Hematology
Patient Stories

Tom Maguire

Bladder Cancer

Tom Maguire

Bladder Cancer

"In 2018 I was diagnosed with muscle invasive bladder cancer, which seemed like it would end my diving, but also provided me a new way to give back."

John Mullarkey, Jr.

Prostate Cancer

John Mullarkey, Jr.

Prostate Cancer

I have always been proactive about my health and started having annual prostate exams when I turned 50 in 2007. My first report was great and showed that my PSA level was undetectable.

Research Profile

Research Program

Research Interests

  • Genitourinary Oncology
  • Immune Related Adverse Events
  • Immunotherapy
Publications

Selected Publications

Zibelman M, Plimack ER. Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm. Oncology. 2016 Feb; 30(2): 160-2. PubMed

Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016 Feb 16;4:8. PubMed

Zibelman M, Wong YN, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.  Investigational New Drugs. 2015 Oct; 33 (5): 1040-7.  PubMed

Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM . A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report from the ClinicalTrials.gov Website. Clinical Genitourinary Cancer. 2015 Apr; 13(2):142-9. PubMed

Ghatalia P, Koenigsberg R, Pisarcik D, Handorf EA, Plimack ER, Geynisman DM, Zibelman M. The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov Website. Kidney Cancer. 2017. December. 1(2):151-159

Zibelman M, Plimack ER. Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake. Immunotherapy. 2018. Mar 1; 10(6): 423-425

Zibelman M, Plimack ER. Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old? Annals of Translational Medicine. 2019. July; 7(Suppl 3): S95

Cole S, Zibelman M, Bertino E, Yucebay F, Reynolds K. Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions. American Society of Clinical Oncology Educational Book 39 (May 17, 2019) 96-104

Dawson NA, Zibelman M, Lindsay T, Feldman RA, Saul M, Gatalica Z, Korn WM, and Heath EI. An emerging landscape for canonical and actionable molecular alterations in primary and metastatic prostate cancer. Molecular Cancer Therapeutics. 2020.19:1373–82. Published on-line March 27, 2020

Anari F, Ramamurthy C, Zibelman M. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncology. 2018 Jun; 14(14): 1409-142

Additional Publications

MyNCBI

Ratings

153 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 4.9
  • 4.9
  • 4.9
  • 4.9
  • 4.8

36 PATIENT COMMENTS

  • No Star Ratings Available December 02, 2020
    Fantastic dr. and hospital.
  • 5.0
    November 28, 2020
    good
  • 5.0
    November 26, 2020
    Good
  • 5.0
    November 18, 2020
    Dr Zibbleman is very concerned about my health!
  • 5.0
    October 30, 2020
    Experience was exceptional all my visits have been good. No complaints what so ever
  • 5.0
    October 22, 2020
    Dr. Zibelman has LITERALLY saved my life, and he continues to work with me.
  • 5.0
    October 16, 2020
    all good
  • 5.0
    October 03, 2020
    very satisfied
  • 5.0
    September 21, 2020
    very good
  • 5.0
    July 23, 2020
    Doctor Zibelman is the best!
  • 5.0
    July 23, 2020
    Good experience; before I went to Fox Center, my dentist, when told that I was going to told me that there were good people at Fox Chase Cancer Center. For sure, since I got there my health is greatly improving!!! Thanks to God for Dr. Zibelman and staff!!!
  • 5.0
    July 01, 2020
    Excellent [...]
  • 5.0
    June 25, 2020
    Dr. Z. very clear about issues, needs and treatments, gives me complete confidence in postponing treatments w/ side-effects while knowing he will tell me when we shouldn't wait any longer.
  • 5.0
    June 11, 2020
    was a telemedicine appt. and went well
  • 5.0
    May 22, 2020
    DR ZIBLEMAN WITH STAFF ALWAYS EXCELLENT. WOULD RECOMMEND HIM
  • 5.0
    May 20, 2020
    Do to the COVID-19 my follow up visit after lab work was conducted over the telephone. Everything was conducted as if I was in the office. Very efficient and through.
  • 5.0
    May 17, 2020
    happy with the I received
  • 5.0
    May 16, 2020
    Visit was a phone conversation due to Corona virus call was excellent
  • 5.0
    May 16, 2020
    Nothing to complain about, could not ask for better.
  • 5.0
    March 23, 2020
    [...] was treated with total concern for me.
LOAD MORE

Connect with Fox Chase